Ridgeback Capital Investments L.P. Affimed N.V. Transaction History

Ridgeback Capital Investments L.P.

  • $0
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.32 - $0.62 $4.75 Million - $9.21 Million
14,858,982 New
14,858,982 $9.29 Billion
Q4 2022

Feb 14, 2023
BUY
$1.1 - $2.45 $14.2 Million - $31.6 Million
12,882,610 New
12,882,610 $16 Billion

Others Institutions Holding AFMD

# of Institutions
3
Shares Held
1.09M
Call Options Held
0
Put Options Held
0
View Full List

About Affimed N.V.

AFMD Quotes by TradingView
  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Ridgeback Capital Investments L.P. Portfolio

Follow Ridgeback Capital Investments L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ridgeback Capital Investments L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ridgeback Capital Investments L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email